A novel approach to safer glucocorticoid receptor-targeted anti-lymphoma therapy via REDD1 (Regulated in development and DNA damage 1) inhibition

Glucocorticoids are widely used for therapy of hematological malignancies. Unfortunately, chronic treatment with glucocorticoids commonly leads to adverse effects including skin and muscle atrophy and osteoporosis. We found recently that REDD1 (regulated in development and DNA damage 1) plays centra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Lesovaya, Ekaterina A., Savinkova, Alena V., Morozova, Olga V., Lylova, Evgeniya S., Zhidkova, Ekaterina M., Kulikov, Evgeny P., Kirsanov, Kirill I., Klopot, Anna, Baida, Gleb, Yakubovskaya, Marianna G., Gordon, Leo I., Readhead, Ben, Dudley, Joel T., Budunova, Irina
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7875139/
https://ncbi.nlm.nih.gov/pubmed/32546661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-1111
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados